Thiamine As Adjunctive Therapy for Diabetic Ketoacidosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-11-21

Study Completion Date

2024-10-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a randomized, double-blind, placebo-controlled trial to determine if administration of intravenous thiamine will lead to quicker resolution of acidosis in patients admitted to the hospital with diabetic ketoacidosis. The investigators will secondarily investigate whether thiamine improves cellular oxygen consumption, shortens intensive care unit (ICU) and hospital stay or decreases hospital resource utilization.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prevention of Renal Complications of Diabetes With Thiamine

NCT01725412

Diabetic Nephropathy

UNKNOWN PHASE4

Vitamin B Complex and Diabetic Nephropathy in Type 1 Diabetes

NCT03594240

Plasma Homocysteine HbA1c Level

COMPLETED PHASE3

The Effect of SLC19A3 Inhibition on the Pharmacokinetics of Thiamine

NCT03746106

Vitamin B1 Deficiency Thiamine Deficiency

COMPLETED PHASE4

Type 2 Diabetes and Blood Brain Barrier Improvement

NCT06322212

Type2diabetes

RECRUITING EARLY_PHASE1

Reactive Oxygen Species in the Pathogenesis of Diabetic Complications

NCT00703989

Type 1 Diabetes

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Thiamine (vitamin B1) is a water-soluble vitamin that plays a key role in aerobic glucose metabolism. Thiamine is a cofactor of pyruvate dehydrogenase (PDH), an enzyme that must be activated for entry into the Krebs Cycle for aerobic metabolism. PDH activity is reduced in thiamine deficient states, resulting in a shift in pyruvate metabolism to the anaerobic pathway. This leads to increased lactate production and acidosis. Thiamine loss in the urine, with consequent thiamine deficiency, is not uncommon in diabetes. The investigators' preliminary studies have found that thiamine deficiency in occurs in as many as 39% of patients with DKA, and that thiamine levels are inversely associated with lactate and acidosis. The investigator hypothesizes that treating DKA patients with intravenous thiamine will lead to faster resolution of acidosis and improved aerobic metabolism. The investigator's secondary hypothesis is that thiamine treatment will shorten stays in the ICU and hospital and lead to utilization of fewer hospital resources.

In this randomized, double-blind, placebo-controlled trial, patients admitted to the hospital with DKA who are enrolled in the study will be randomized to either intravenous thiamine (200mg in 0.9% saline) twice daily for two days or an identical volume of 0.9% saline on the same schedule. The investigator's primary outcome is change in bicarbonate over the 24 hours following enrollment, with measurements at 0, 6, 12, 18, 24 hours, using a linear mixed-effects model. Secondarily, patients will be stratified by Type I and Type II DM. Additionally, a pre-planned sub-analysis of thiamine deficient subjects will be performed.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetic Ketoacidosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Thiamine

200mg IV thiamine in 50mL 0.9% saline twice daily for 2 days

Group Type EXPERIMENTAL

200mg IV thiamine in 50mL 0.9% saline

Intervention Type DRUG

Thiamine 200mg IV every 12 hours for 2 days

Placebo

100mL 0.9% saline twice daily for two days

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

50mL 0.9% saline

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

200mg IV thiamine in 50mL 0.9% saline

Thiamine 200mg IV every 12 hours for 2 days

Intervention Type DRUG

Placebo

50mL 0.9% saline

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Vitamin B1

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Bicarbonate ≤15 mEq/L
* Anion gap \> 12 mEq/L
* Blood pH≤ 7.24 (if already obtained by clinical team)
* Urine ketones (qualitative) or serum ketones (β-hydroxybutyric acid) \> 3 mmol/L
* Enrollment within 6 hours of presentation

Exclusion Criteria

* Current thiamine supplementation ≥ 6 milligrams per day (i.e., more than a multivitamin)
* Competing causes of severe acidosis including seizure, carbon monoxide poisoning, cyanide toxicity, cardiac arrest, liver dysfunction (specifically defined as known cirrhosis)
* Known allergy to thiamine
* Competing indication for thiamine administration as judged by the clinical team (e.g., significant alcohol use)
* Research-protected populations (pregnant women and prisoners)
* Patient enrolled previously in same study
* Code status of Do Not Resuscitate/Do Not Intubate (DNR/DNI) or Comfort Measures Only (CMO)

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No